Cargando…
Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits th...
Autores principales: | Kameda, Hideto, Suzuki, Miyuki, Takeuchi, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155225/ https://www.ncbi.nlm.nih.gov/pubmed/21901078 |
Ejemplares similares
-
Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012) -
What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012) -
Platelet-Derived Microparticles and Autoimmune Diseases
por: Li, Xiaoshuai, et al.
Publicado: (2023) -
Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010) -
Pathogenic role of platelets in rheumatoid arthritis and systemic autoimmune diseases: Perspectives and therapeutic aspects
por: Harifi, Ghita, et al.
Publicado: (2016)